8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): September 17, 2015

ENDOLOGIX, INC.

(Exact name of registrant as specified in its charter)

Delaware	000-28440	68-0328265
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

2 Musick, Irvine, CA	92618
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (949) 595-7200

N/A

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation

of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On September 17, 2015, Endologix, Inc. (the “Company”) announced the appointment of Vaseem Mahboob, age 46, to serve as its Chief Financial Officer, effective October 15, 2015. Mr. Mahboob will replace Shelley B. Thunen, who previously announced her retirement from the Company. Ms. Thunen will remain available to the Company to assist with the transition of the office to Mr. Mahboob.

Mr. Mahboob has served as a senior executive officer of several business segments within the General Electric Company, a publicly-held infrastructure and financial services company, for 16 years, with expertise across all areas of finance and accounting. Prior to joining the Company, Mr. Mahboob served as Chief Financial Officer, Eastern and African Growth Markets, of GE Healthcare, from January 2013 to September 2015. From November 2010 to December 2012, Mr. Mahboob served as Chief Financial Officer, Global Ultrasound Business, of GE Healthcare. From September 2006 to October 2010, Mr. Mahboob served as Chief Financial Officer, Global Magnetic Resonance Business, of GE Healthcare. From October 2004 to August 2006, Mr. Mahboob served as Global Manufacturing Finance Manager of GE Advanced Materials. Prior that Mr. Mahboob held several leadership positions within GE’s corporate audit staff. Mr. Mahboob received a Bachelor of Engineering in Computer Science from Bangalore University and an M.B.A. in Financial Markets and Institutions & Information Systems from the State University of New York, Buffalo, New York.

In connection with his employment, Mr. Mahboob will receive an annual base salary of $350,000 and will be entitled to receive an annual cash bonus of up to 50% of his base salary based upon his achievement of certain performance objectives. The Company also granted Mr. Mahboob restricted stock units with an underlying value of $750,000, which will vest upon the Company and Mr. Mahboob achieving certain performance milestones, and options to purchase shares of the Company’s common stock with an underlying value of $750,000, which will vest 25% on the first anniversary of the grant date and in 36 equal monthly installments thereafter. The restricted stock units and stock options granted to Mr. Mahboob are subject to accelerated vesting in the event of a change in control of the Company. In addition, Mr. Mahboob will be entitled to certain perquisites, such as group life insurance and such other benefit programs offered generally by the Company to is other senior executives, and severance compensation upon the occurrence of certain events.

The Company issued a press release on September 17, 2015, announcing the Company’s appointment of Mr. Mahboob as its Chief Financial Officer, a copy of which is attached hereto as Exhibit 99.1.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits

Exhibit No.	Description
99.1	Press Release, dated September 17, 2015.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ENDOLOGIX, INC.
Date: September 17, 2015	/s/ John McDermott
	John McDermott
	Chief Executive Officer

EX-99.1

Exhibit 99.1

COMPANY CONTACTS:	INVESTOR CONTACTS:
Endologix, Inc.	The Ruth Group
John McDermott, CEO	Nick Laudico (646) 536-7030
(949) 595-7200	Zack Kubow (646) 536-7020
www.endologix.com

Endologix Appoints Vaseem Mahboob as Chief Financial Officer

IRVINE, Calif., September 17 2015 - Endologix, Inc. (Nasdaq: ELGX), developer and marketer of innovative treatments for aortic disorders, announced today that it has appointed Vaseem Mahboob to the position of Chief Financial Officer, effective October 15, 2015. Mr. Mahboob succeeds Shelley Thunen, who is resigning as part of the Company’s previously announced CFO transition.

John McDermott, Chief Executive Officer of Endologix, said, “We are excited to have Vaseem join the Endologix executive leadership team. He has deep experience leading the global financial operations of multi-billion dollar healthcare businesses at GE Healthcare, with a track record of improving performance and successfully implementing strategic growth plans. We believe his extensive experience will strengthen our global financial management systems and position us to achieve our long-term growth aspirations.”

Mr. McDermott added, “I want to thank Shelley Thunen for her service as CFO and wish her the best in her future endeavors.”

Vaseem Mahboob joins Endologix after serving in several financial leadership positions at GE Healthcare, a worldwide leader in medical device development and distribution. His most recent role was Chief Financial Officer of their Global IT business. Prior to this position he was the Chief Financial Officer of their Eastern and African Emerging Markets where he oversaw financial operations for medical device distribution sales and service spanning 84 countries and four zones including Russia, Turkey, Middle East and Africa. Prior to this role, Mr. Mahboob was Chief Financial Officer of GE Healthcare’s Global Ultrasound Business that is the most global and profitable within GE Healthcare. Mr. Mahboob also served as CFO of GE Healthcare’s Global Magnetic Resonance (MRI) Business, along with several other global financial leadership positions.

Mr. Mahboob received a B.A. in Engineering from Bangalore University, and a Masters of Business Administration (MBA) in Financial Markets and Institutions & Information Systems from State University

Exhibit 99.1

of New York, Buffalo, NY. He is also a graduate of GE’s highly regarded internal corporate audit staff where he was a senior audit manager.

About Endologix, Inc.

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of abdominal aortic aneurysms (AAA). AAA is a weakening of the wall of the aorta, the largest artery in the body, resulting in a balloon-like enlargement. Once AAA develops, it continues to enlarge and, if left untreated, becomes increasingly susceptible to rupture. The overall patient mortality rate for ruptured AAA is approximately 80%, making it a leading cause of death in the U.S. Additional information can be found on Endologix's website at www.endologix.com.